Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Gadopentetate dimeglumine

×

Overview

What is Magnevist?

Magnevist (brand of gadopentetate dimeglumine) injection is the N-methylglucamine salt of the gadolinium complex of diethylenetriamine pentaacetic acid, and is an injectable contrast medium for magnetic resonance imaging (MRI). Magnevist Injection is provided as a sterile, clear, colorless to slightly yellow aqueous solution for intravenous injection.

Magnevist Injection is a 0.5-mol/L solution of 1-deoxy-1-(methylamino)-D-glucitol dihydrogen [N,N-bis[2-[bis(carboxymethyl)amino]ethyl] glycinato (5-) ]gadolinate(2-)(2:1) with a molecular weight of 938, an empirical formula of CHGdNO, and has the following structural formula:

Each mL of Magnevist injection contains 469.01 mg gadopentetate dimeglumine, 0.99 mg meglumine, 0.40 mg diethylenetriamine pentaacetic acid, and water for injection. Magnevist injection contains no antimicrobial preservative.

Magnevist Injection has a pH of 6.5 to 8.0. Pertinent physicochemical data are noted below:

Magnevist injection has an osmolality 6.9 times that of plasma, which has an osmolality of 285 mOsmol/kg water. Magnevist injection is hypertonic under conditions of use.



What does Magnevist look like?



What are the available doses of Magnevist?

Magnevist contains 0.5 mmol gadopentetate dimeglumine/mL (equivalent to 469.01 mg gadopentetate dimeglumine/mL) and is available in vials and prefilled syringes. ()

What should I talk to my health care provider before I take Magnevist?

How should I use Magnevist?

Magnevist injection is indicated for use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. Magnevist injection has been shown to facilitate visualization of intracranial lesions including but not limited to tumors.

The recommended dosage of Magnevist injection is 0.2 mL/kg (0.1 mmol/kg) administered intravenously, at a rate not to exceed 10 mL per 15 seconds. Dosing for patients in excess of 286 lbs has not been studied systematically.

To ensure complete injection of Gadopentetate dimeglumine, administer 5-mL normal saline flush after the injection. The imaging procedure should be completed within 1 hour of injection of Magnevist injection.

Visually inspect for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored, if particulate matter is present or if the container appears damaged.

Discard any unused portion in accordance with regulations dealing with the disposal of such materials.


What interacts with Magnevist?

Sorry No Records found


What are the warnings of Magnevist?

Sorry No Records found


What are the precautions of Magnevist?

Sorry No Records found


What are the side effects of Magnevist?

Sorry No records found


What should I look out for while using Magnevist?

Magnevist is contraindicated in patients with:


What might happen if I take too much Magnevist?

Systemic consequences associated with overdosage of Magnevist injection have not been reported.


How should I store and handle Magnevist?

Store olanzapine tablets at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].Protect olanzapine tablets from light and moisture. Store olanzapine tablets at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].Protect olanzapine tablets from light and moisture. Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.